It looks like Dr. Brian Kennedy and Dr. Mikhail Blagosklonny will find themselves in great company.
Presentation Title: Effects of mTOR Inhibition on Immunosenescence in Elderly Humans
Abstract: Inhibition of the mTOR pathway extends lifespan in all species studied to date, and in mice delays the onset of aging-related diseases and co-morbidities. However, it is unknown if mTOR inhibition impacts aging in humans. To begin to assess the effects of mTOR inhibition on human aging-related phenotypes, we evaluated whether the mTOR inhibitor RAD001 ameliorates immunosenescence (the decline in immune function during aging) in elderly volunteers, as assessed by response to influenza vaccination. Our findings suggest that RAD001 enhanced the response to influenza vaccine in elderly volunteers at doses that were well tolerated. These results suggest that mTOR inhibition has beneficial effects on immunosenescence in elderly volunteers. It remains to be determined if mTOR inhibitors improve other aging-related conditions in humans.
Authors: J. Mannick1*, G. Del Giudice2, M. Lattanzi2, N. Valiante2, J. Praestgaard1, B. Huang1, M. Lonetto1, H. Maecker3, J. Kovarik1, S. Carson4, D. Glass1, L. Klickstein1
Affiliations: 1Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
2Novartis Vaccines and Diagnostics, Siena, Italy, and Cambridge, MA, USA.
3Stanford University School of Medicine, Stanford, CA, USA
4 Southern Clinical Trials, Christchurch, New Zealand